Rubedo Life Sciences has reported early clinical results showing its experimental drug RLS-1496 reduced precancerous skin lesions called actinic keratosis by 46% after just four weeks. Actinic keratosis affects an estimated 58 million Americans and can progress to squamous cell carcinoma if untreated. What sets this trial apart is not just efficacy but tolerability — patients reported only minimal irritation, a stark contrast to current treatments that cause weeks of redness, peeling, and pain. That tolerability gap is a major reason many patients avoid or abandon treatment. RLS-1496 works by targeting senescent cells — dysfunctional aging cells that accumulate in tissues and drive inflammation. The drug acts through the GPX4 biological pathway to selectively clear these cells while supporting recovery of healthier neighboring cells.
